Search research articles
Contact Us
Filters
Showing results (191-200 of 231) with videos related to
Page
of 24
Sort By:
Journal for Immunotherapy of Cancer
|
November 29, 2023
Phase I/Ib, open-label, multicenter, dose-escalation study of the anti-TGF-β monoclonal antibody, NIS793, in combination with spartalizumab in adult patients with advanced tumors
Todd M Bauer, Armando Santoro, Chia-Chi Lin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 3, 2024
Correction: Phase I/Ib Clinical Trial of Sabatolimab, an Anti-TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti-PD-1 Antibody, in Advanced Solid Tumors
Giuseppe Curigliano, Hans Curigliano, Nicolas Mach, et al.
The Oncologist
|
April 22, 2025
Phase I study of oral metronomic gemcitabine (D07001) in patients with advanced solid tumors
Nai-Jung Chiang, Jih-Hsiang Lee, Ming-Huang Chen, et al.
Cancer Immunology, Immunotherapy : CII
|
July 3, 2021
First-in-human phase 1 study of budigalimab, an anti-PD-1 inhibitor, in patients with non-small cell lung cancer and head and neck squamous cell carcinoma
Antoine Italiano, Philippe A Cassier, Chia-Chi Lin, et al.
Annals of Surgical Oncology
|
February 8, 2011
Polymorphism in epidermal growth factor receptor intron 1 predicts prognosis of patients with esophageal cancer after chemoradiation and surgery
Jang-Ming Lee, Shi-Yi Yang, Pei-Wen Yang, et al.
Journal for Immunotherapy of Cancer
|
March 18, 2020
A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti-PD-1 antibody, in patients with advanced solid tumors
Aung Naing, Justin F Gainor, Hans Gelderblom, et al.
British Journal of Cancer
|
June 30, 2018
Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012
Ranee Mehra, Tanguy Y Seiwert, Shilpa Gupta, et al.
Cancer
|
December 17, 2013
An open-label, single-arm, phase 2 trial of the Polo-like kinase inhibitor volasertib (BI 6727) in patients with locally advanced or metastatic urothelial cancer
Walter M Stadler, David J Vaughn, Guru Sonpavde, et al.
Journal of Cancer
|
May 29, 2018
Tumor PD-L1 Expression and Clinical Outcomes in Advanced-stage Non-Small Cell Lung Cancer Patients Treated with Nivolumab or Pembrolizumab: Real-World Data in Taiwan
Shu-Yung Lin, Ching-Yao Yang, Bin-Chi Liao, et al.
Thyroid : Official Journal of the American Thyroid Association
|
August 11, 2022
Multikinase Inhibitors for the Treatment of Asymptomatic Radioactive Iodine-Refractory Differentiated Thyroid Cancer: Global Noninterventional Study (RIFTOS MKI)
Marcia S Brose, Johannes W A Smit, Chia-Chi Lin, et al.
Page
of 24
Search research articles
Search
Showing results (191-200 of 231) with videos related to
Sort By:
Page
of 24
Journal for Immunotherapy of Cancer
|
November 29, 2023
Phase I/Ib, open-label, multicenter, dose-escalation study of the anti-TGF-β monoclonal antibody, NIS793, in combination with spartalizumab in adult patients with advanced tumors
Todd M Bauer, Armando Santoro, Chia-Chi Lin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 3, 2024
Correction: Phase I/Ib Clinical Trial of Sabatolimab, an Anti-TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti-PD-1 Antibody, in Advanced Solid Tumors
Giuseppe Curigliano, Hans Curigliano, Nicolas Mach, et al.
The Oncologist
|
April 22, 2025
Phase I study of oral metronomic gemcitabine (D07001) in patients with advanced solid tumors
Nai-Jung Chiang, Jih-Hsiang Lee, Ming-Huang Chen, et al.
Cancer Immunology, Immunotherapy : CII
|
July 3, 2021
First-in-human phase 1 study of budigalimab, an anti-PD-1 inhibitor, in patients with non-small cell lung cancer and head and neck squamous cell carcinoma
Antoine Italiano, Philippe A Cassier, Chia-Chi Lin, et al.
Annals of Surgical Oncology
|
February 8, 2011
Polymorphism in epidermal growth factor receptor intron 1 predicts prognosis of patients with esophageal cancer after chemoradiation and surgery
Jang-Ming Lee, Shi-Yi Yang, Pei-Wen Yang, et al.
Journal for Immunotherapy of Cancer
|
March 18, 2020
A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti-PD-1 antibody, in patients with advanced solid tumors
Aung Naing, Justin F Gainor, Hans Gelderblom, et al.
British Journal of Cancer
|
June 30, 2018
Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012
Ranee Mehra, Tanguy Y Seiwert, Shilpa Gupta, et al.
Cancer
|
December 17, 2013
An open-label, single-arm, phase 2 trial of the Polo-like kinase inhibitor volasertib (BI 6727) in patients with locally advanced or metastatic urothelial cancer
Walter M Stadler, David J Vaughn, Guru Sonpavde, et al.
Journal of Cancer
|
May 29, 2018
Tumor PD-L1 Expression and Clinical Outcomes in Advanced-stage Non-Small Cell Lung Cancer Patients Treated with Nivolumab or Pembrolizumab: Real-World Data in Taiwan
Shu-Yung Lin, Ching-Yao Yang, Bin-Chi Liao, et al.
Thyroid : Official Journal of the American Thyroid Association
|
August 11, 2022
Multikinase Inhibitors for the Treatment of Asymptomatic Radioactive Iodine-Refractory Differentiated Thyroid Cancer: Global Noninterventional Study (RIFTOS MKI)
Marcia S Brose, Johannes W A Smit, Chia-Chi Lin, et al.
Page
of 24